Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206167 · ClinicalTrials.gov registry record · Phase 3
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,600
- Enrollment target
NCT00206167: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00206167 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 1,600 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (107% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206167, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,600 participants
- Enrollment target
Study Summary
The purpose of this study is to compare Symbicort in a pressurized metered-dose inhaler (pMDI) with formoterol and placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Interventions
- DRUG Formoterol Turbuhaler
- DRUG Budesonide/formoterol pMDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
What the finished NCT00206167 record still lists
NCT00206167 is an interventional study that assigns participants to a tested intervention. Its 1,600 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (107% higher).
The record links to 0 conditions, and to 2 interventions - of which Formoterol Turbuhaler is the first listed.
NCT00206167 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00206167 about?
NCT00206167 is a clinical study titled "A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD". The purpose of this study is to compare Symbicort in a pressurized metered-dose inhaler (pMDI) with formoterol and placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT00206167?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,600 participants. The study started on 2005-04. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00206167?
The interventions under investigation include: Formoterol Turbuhaler (DRUG), Budesonide/formoterol pMDI (DRUG).
Who is sponsoring clinical trial NCT00206167?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00206167's enrollment target sits among peer trials
1,600 142nd of 2000 higher than 1,855 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- NCT04314401 · 1,600 participants
National Cancer Institute "Cancer Moonshot Biobank"
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia